In Brief: Nycomed's Omniscan
Nycomed's Omniscan: Imaging agent adds two new indications and a new dosage regimen to its labeling. Under three supplemental NDAs approved Feb. 5, Omniscan (gadodiamide) is indicated for enhancement of magnetic resonance imaging of the internal organs of adults, MRI enhancement of the CNS in children, and for an increase in the cumulative dose from .1 mmol/kg to .3 mmol/kg for MRI of the CNS in adults...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth